Researchers from MIT have devised a way for T cells to be engineered to carry nanoparticle ‘backpacks’ that can deliver the payload only when interacting with the target tumour cells.
Sanofi will support development of polypeptides, gene therapy, monoclonal antibodies and multi-specific antibodies through the expansion of its R&D plant in Chengdu, Sichuan province, China.
Infusing CAR T-cells directly into the brain, rather than into the blood intravenously, could improve the immunotherapy’s effectiveness and produce fewer side effects, say researchers.
Plasticell, alongside Great Ormond Street Hospital and the UCL Institute of Child Health, have announced they will collaborate to develop technology to better develop and manufacture gene therapies.
WuXi Biologics has announced it will undertake its first collaborative project to develop and manufacture ‘heavy chain only’ antibodies, through an agreement with Harbour BioMed.
WuXi Biologics has started building its antibody-drug conjugate (ADC) centre in Wuxi City, China, where it will offer biologics conjugate services for clients.
With $12m in Series C financing, AbSci is looking to tackle the antibody market by accelerating innovation and driving down manufacturing costs using its synthetic biology platform, says CEO.
Cellectis has built a switch into a chimeric antigen receptor (CAR) T-cell to provide an efficient way to eliminate the therapy if it becomes a threat to patient safety.
Eisai says it is creating a research facility for ‘genetics-guided dementia discovery’ in the US and joining a Japanese industry-academia-government collaboration aimed at developing nucleic acid-based drugs.
Many unanswered questions surrounding the nascent biosimilar market are creating challenges – though less regulated markets may benefit from 'less well defined' definitions, says analyst.
Parker Bioscience outlines its planned investment to meet demand as the industry shifts from traditional processes to biological – for which single-use products are critical, says exec.
WuXi Biologics has announced plans to build a $60m manufacturing facility – offering continuous manufacturing options – for clinical and commercial production in the US.
Microbiome start-up will receive up to €454 million in upfront and milestone payments
UK-based Microbiotica will collaborate with Roche-owned biotechnology group Genentech in the hunt for new microbiome-based therapeutics and biomarkers for its inflammatory bowel disease (IBD) pipeline.
Syngene International has inked a non-exclusive partnering agreement with the emerging immuno-oncology company Zumutor Biologics after collaborating for more than a year.
AveXis – a Novartis company – has added a manufacturing facility in North Carolina to its site network, where it will make investigational therapies for neurological genetic diseases.
WuXi Biologics is expanding its manufacturing site network to Singapore with the construction of a $60m facility for clinical and small volume commercial production.
CDMO WuXi Biologics has announced plans to build a biologics centre in China, where it will develop and manufacture large molecule drugs for clinical and commercial production.
TapImmune CEO says Marker Therapeutics’ data could be game-changing, as the two companies set to merge and disrupt the field of immuno-oncology and cell therapy.
Eli Lilly has announced plans to buy AurKa Pharma and its lead oncology compound AK-01, just days after purchasing the immuno-oncology firm Armo Biosciences.
In a move aimed to bolster its immuno-oncology program, Eli Lilly and Company has acquired Armo BioSciences for $50 per share, or approximately $1.6bn.
Lonza has inked a long-term contract extension for the commercial supply of Proteon’s lead development candidate as its Ph III clinical trial nears completion.
The patent will help PlantForm Corporation continue to advance its platform for manufacturing antibody and protein drugs, as the company looks to bring products to market, says CEO.
Sanofi has awarded Meditope Biosciences a BioLabs’ “Golden Ticket” to support the development of its bioconjugation platform and create new antibody-based therapeutic constructs.
Researchers at the Wyss Institute are teaming up with Cellectis to develop “ultra-safe” human cells resistant to infection – which could enable more effective ways to manufacture protein therapeutics, vaccines, and cell therapies.
Janssen Biotech has entered into a definitive agreement to acquire BeneVir Biopharm, a deal which looks to advance Janssen’s immunotherapy platform and capabilities.
Catalent is planning to add capacity at two of its biologics manufacturing facilities, setting it up to grow in an area in which demand continues to outstrip supply.
Philadelphia, Pennsylvania has the logistics, capabilities, and expertise required to advance next-generation therapies in the US, says industry expert.